MEK1

Spirita Oncology, LLC Initiates a Phase 1 Clinical Trial of the Anti-Cancer Agent E6201 in Combination with Dabrafenib in Patients with Central Nervous System Metastases from BRAF V600 Mutated Metastatic Melanoma

Retrieved on: 
Wednesday, November 30, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Linda, BBB, Melanoma, Patient, BRAF, Central nervous system, Death, Brain, CNS, MEK1, ATP, Survival, MEK, Medical imaging

Spirita Oncology, LLC, has initiated a Phase 1 clinical trial of anti-cancer agent E6201 in combination with dabrafenib in patients with BRAF V600-mutated metastatic melanoma that has spread to the central nervous system.

Key Points: 
  • Spirita Oncology, LLC, has initiated a Phase 1 clinical trial of anti-cancer agent E6201 in combination with dabrafenib in patients with BRAF V600-mutated metastatic melanoma that has spread to the central nervous system.
  • There are approximately 47,000 new cases of metastatic melanoma in the U.S. each year, with approximately 10,000 deaths.
  • Targeted therapies and immune checkpoint inhibitors have improved overall survival for metastatic melanoma patients with brain metastases.
  • Exceptional responses were seen with E6201 monotherapy in patients with melanoma brain metastases in our prior Phase 1 studies.

MAP Kinase Kinase 1 Inhibitors Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 30, 2021
Health, Biotechnology, Royal commission, Patient, RAS, News, Discovery, Pancreatic cancer, Ovarian cancer, Cancer, Protein, Mitogen-activated protein kinase, Lung cancer, MEK, MAPK, MEK2, EGFR, LGG, Clinical trial, RAF, Food, Disease, Therapy, NF1, Melanoma, Endometrial cancer, Colorectal cancer, Orphan drug, Fast Track, MAP, Selumetinib, III, FDA, European Commission, MEK1, Inhibitor, II, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Growth, Fertilizer, Pharmaceutical industry

The "MAP Kinase Kinase 1 Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "MAP Kinase Kinase 1 Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "MAP kinase kinase 1 inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in MAP kinase kinase 1 inhibitors pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence MAP kinase kinase 1 inhibitors R&D.
  • The therapies under development are focused on novel approaches for MAP kinase kinase 1 inhibitors.

SpringWorks Therapeutics Announces Full Enrollment of Phase 2b ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with NF1-Associated Plexiform Neurofibromas

Retrieved on: 
Monday, November 29, 2021
Royal commission, Private Securities Litigation Reform Act, Patient, Trial of the century, Safety, Cancer, AE, Industry, Conference, Neoplasm, MEK, MAPK, Precision medicine, LGG, MEK2, Pigment, Solution, Food, Disease, COVID-19, Pain, Goal, NF1, Nasdaq, Twitter, Survival, Research, Neurofibromatosis, GLOBE, Adult, Incidence, Life expectancy, Orphan drug, Fast Track, MRI, United, FDA, European Commission, Therapy, LinkedIn, PN, MEK1, Genetic disorder, Disability, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Degenerative disease, Pharmaceutical industry

SpringWorks expects to provide an update on anticipated ReNeu trial timelines and milestones at an upcoming company-sponsored R&D Day.

Key Points: 
  • SpringWorks expects to provide an update on anticipated ReNeu trial timelines and milestones at an upcoming company-sponsored R&D Day.
  • Plexiform neurofibromas can cause severe disfigurement, pain, and functional impairment, and patients living with these devastating tumors are in need of new treatments.
  • The ReNeu trial is a multi-center, open-label Phase 2b trial evaluating the efficacy, safety, and tolerability of mirdametinib in patients two years of age and older with an inoperable NF1-associated PN causing significant morbidity.
  • Patients receive mirdametinib at a dose of 2 mg/m2 twice daily (maximum dose of 4 mg twice daily) without regard to food.

Recursion is Granted Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis

Retrieved on: 
Wednesday, September 29, 2021
Food, Pharmacokinetics, Standard of care, Malignant transformation, Adenoma, MEK2, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Anti–vascular endothelial growth factor therapy, Colon, NASDAQ, FDA, Patient, Engineering, Chemistry, FAP, LinkedIn, Degenerative disease, Colectomy, APC, Biology, Twitter, Bias, Death, Medicine, MEK1, Disease, Risk, Stomach, Algorithm, Prognosis, Polyp, Automation, Colorectal cancer, Drug discovery, Recursion, Safety, Machine learning, Duodenum, SALT, Pharmaceutical industry

SALT LAKE CITY, Sept. 29, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for REC-4881 for the potential treatment of familial adenomatous polyposis (FAP).

Key Points: 
  • SALT LAKE CITY, Sept. 29, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for REC-4881 for the potential treatment of familial adenomatous polyposis (FAP).
  • REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce tumor size in FAP patients.
  • The FDA designates orphan products to support the development and evaluation of new treatments for rare diseases.
  • "The orphan drug designation for REC-4881 is an important addition to our work to develop this medicine to treat patients with FAP, for which there is significant unmet need," said Ramona Doyle, M.D.